The hypothesis tested predicted that PBMC of these patients might be enriched in CD4+CD25+ Treg, which, by virtue of downregulating antitumour immune functions, could contribute to the progression or recurrence of head and neck cancer. This evidence concerns the gene CD4 and head and neck cancer.